Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer. Founded in 2009, the organization was formerly known as Harvard Apparatus Regenerative Technology, Inc. before rebranding as Biostage, Inc. in March 2016.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 13, 2023 | – | -$0.12 | |
| Aug 2, 2023 | – | -$0.19 | |
| May 12, 2023 | – | -$0.24 | |
| Mar 30, 2023 | – | -$0.12 | |
| Nov 14, 2022 | – | -$0.10 | |
| Aug 4, 2022 | – | -$0.12 |